Tetraphase Pharmaceuticals tphase.com


Public lists: Pharma Startups (4732)

Tetraphase Pharmaceuticals discovers and develops new tetracycline antibiotics to treat drug resistant bacterial infections using technology developed by Dr. Andrew Myers Professor of Chemistry and Chemical Biology at Harvard that aims to enable for a time the total synthesis of tetracyclines. This technology aims to allow modification of the core molecule and synthesis of thousands of new tetracycline compounds that were previously inaccessible expanding the universe of an existing highly succe...Show all

Tetraphase Pharmaceuticals discovers and develops new tetracycline antibiotics to treat drug resistant bacterial infections using technology developed by Dr. Andrew Myers Professor of Chemistry and Chemical Biology at Harvard that aims to enable for ...Show all

Company (IPO / Went public)

Phone: 617-715-3551

Fax:

480 Arsenal Street
Suite 110
Watertown, 02472
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Tetraphase Pharmaceuticals $170M Mar 20, 2013
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Tetraphase Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

Affinium Pharmaceuticals

Toronto, Ontario, Canada
Alive / ActiveAffinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.Login to see details

KAI Pharmaceuticals

South San Francisco, California, United States
AcquiredKAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of PKC to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, ...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Tetracycline compounds Aug 27, 2010 Apr 18, 2017 Patent
Tetracycline compounds Aug 30, 2013 Feb 21, 2017 Patent
Tetracycline compounds Mar 01, 2017 Application
Tetracyline compounds Jan 06, 2017 Application
C7-fluoro substituted tetracycline compounds Nov 09, 2016 Application
See all 8 patents